Multiple Myeloma: International Myeloma Foundation : • webcasts   : webcasts from medical meetings

ASH 2007 WEBCAST

We are pleased to present these overviews of the 49th Annual American Society of Hematology Meeting (ASH) that was held in Atlanta, Georgia from December 8-11, 2007.

share |

ASH 2007

previous next

view all

Newly Diagnosed Myeloma

Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.

Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma

Shaji Kumar, MD
Mayo Clinic
Rochester, MN

Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis

Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors

Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens

Antonio Palumbo, MD
Ospedale Molinette
Torino, Italy
Member,IMF Board of Scientific Advisors

Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma

Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York
Member, IMF Board of Scientific Advisors

Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls

Craig B. Reeder, MD
Mayo Clinic
Scottsdale, Arizona

Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma

Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
Member, IMF Board of Scientific Advisors

Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232

Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial

Anders Waage, MD
University Hospital
Trondheim, Norway

Relapsed/Refractory Myeloma

Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)

Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors

previous next

view all